{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T18:26:48Z","timestamp":1774031208617,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"DOI":"10.7759\/cureus.105563","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:37:25Z","timestamp":1774028245000},"source":"Crossref","is-referenced-by-count":0,"title":["Timing of DOAC Initiation After Atrial Fibrillation-Related Acute Ischemic Stroke: A Unified Protocol Harmonizing Clinical Safety and Imaging-Based Precision in the Post-CATALYST Era"],"prefix":"10.7759","author":[{"given":"Deb","family":"Mojumder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apurva","family":"Popat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.116.012865","article-title":"Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes","volume":"47","author":"Henninger N","year":"2016","unstructured":"Henninger N, Goddeau RP Jr, Karmarkar A, Helenius J, McManus DD. Atrial fibrillation is associated with a worse 90-day outcome than other cardioembolic stroke subtypes. Stroke. 2016, 47:1486-92. 10.1161\/STROKEAHA.116.012865","journal-title":"Stroke"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1159\/000015878","article-title":"Clinical predictors of early embolic recurrence in presumed cardioembolic stroke","volume":"8","author":"Arboix A","year":"1998","unstructured":"Arboix A, Garc\u00eda-Eroles L, Oliveres M, Massons JB, Targa C. Clinical predictors of early embolic recurrence in presumed cardioembolic stroke. Cerebrovasc Dis. 1998, 8:345-53. 10.1159\/000015878","journal-title":"Cerebrovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1177\/2396987319841187","article-title":"Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline","volume":"4","author":"Klijn CJ","year":"2019","unstructured":"Klijn CJ, Paciaroni M, Berge E, et al.. Antithrombotic treatment for secondary prevention of stroke and other thromboembolic events in patients with stroke or transient ischemic attack and non-valvular atrial fibrillation: a European Stroke Organisation guideline. Eur Stroke J. 2019, 4:198-223. 10.1177\/2396987319841187","journal-title":"Eur Stroke J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30356-9","article-title":"Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation","volume":"18","author":"Seiffge DJ","year":"2019","unstructured":"Seiffge DJ, Werring DJ, Paciaroni M, et al.. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019, 18:117-26. 10.1016\/S1474-4422(18)30356-9","journal-title":"Lancet Neurol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff CT","year":"2014","unstructured":"Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014, 383:955-62. 10.1016\/S0140-6736(13)62343-0","journal-title":"Lancet"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger CB","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, et al.. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011, 365:981-92. 10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.125.051088","article-title":"Risk of intracranial hemorrhage with apixaban versus aspirin therapy: a meta-analysis of randomized controlled trials","volume":"56","author":"Daghlas I","year":"2025","unstructured":"Daghlas I, Lieberman OJ, Suleiman L, Kim AS, Hemphill JC. Risk of intracranial hemorrhage with apixaban versus aspirin therapy: a meta-analysis of randomized controlled trials. Stroke. 2025, 56:2318-23. 10.1161\/STROKEAHA.125.051088","journal-title":"Stroke"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus later anticoagulation for stroke with atrial fibrillation","volume":"388","author":"Fischer U","year":"2023","unstructured":"Fischer U, Koga M, Strbian D, et al.. Early versus later anticoagulation for stroke with atrial fibrillation. N Engl J Med. 2023, 388:2411-21. 10.1056\/NEJMoa2303048","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02197-4","article-title":"Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial","author":"Werring DJ","year":"2024","unstructured":"Werring DJ, Dehbi HM, Ahmed N, et al.. Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial. Lancet. 2024, 10.1016\/S0140-6736(24)02197-4","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (timing): a registry-based randomized controlled noninferiority study","volume":"146","author":"Oldgren J","year":"2022","unstructured":"Oldgren J, \u00c5sberg S, Hijazi Z, Wester P, Bertilsson M, Norrving B. Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (timing): a registry-based randomized controlled noninferiority study. Circulation. 2022, 146:1056-66. 10.1161\/CIRCULATIONAHA.122.060666","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00439-8","article-title":"Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)","volume":"406","author":"Dehbi HM","year":"2025","unstructured":"Dehbi HM, Fischer U, Asberg S, et al.. Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST). Lancet. 2025, 406:43-51. 10.1016\/S0140-6736(25)00439-8","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/STR.0000000000000375","article-title":"2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association","volume":"52","author":"Kleindorfer DO","year":"2021","unstructured":"Kleindorfer DO, Towfighi A, Chaturvedi S, et al.. 2021 Guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association\/American Stroke Association. Stroke. 2021, 52:e364-467. 10.1161\/STR.0000000000000375","journal-title":"Stroke"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder IC","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV, et al.. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024, 45:3314-414. 10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.1450","article-title":"Early vs late anticoagulation in minor, moderate, and major ischemic stroke with atrial fibrillation: post hoc analysis of the ELAN randomized clinical trial","volume":"81","author":"Goeldlin MB","year":"2024","unstructured":"Goeldlin MB, Hakim A, Branca M, et al.. Early vs late anticoagulation in minor, moderate, and major ischemic stroke with atrial fibrillation: post hoc analysis of the ELAN randomized clinical trial. JAMA Neurol. 2024, 81:693-702. 10.1001\/jamaneurol.2024.1450","journal-title":"JAMA Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2025.0285","article-title":"Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation: a pragmatic, response-adaptive randomized clinical trial","volume":"82","author":"Warach SJ","year":"2025","unstructured":"Warach SJ, Davis LA, Lawrence P, et al.. Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation: a pragmatic, response-adaptive randomized clinical trial. JAMA Neurol. 2025, 82:470-6. 10.1001\/jamaneurol.2025.0285","journal-title":"JAMA Neurol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly SJ","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S, et al.. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009, 361:1139-51. 10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel MR","year":"2011","unstructured":"Patel MR, Mahaffey KW, Garg J, et al.. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011, 365:883-91. 10.1056\/NEJMoa1009638","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.84.2.527","article-title":"Stroke prevention in atrial fibrillation study. Final results","volume":"84","year":"1991","unstructured":"Stroke prevention in atrial fibrillation study. Final results. Circulation. 1991, 84.527-39. 10.1161\/01.cir.84.2.527","journal-title":"Circulation"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart RG","year":"2007","unstructured":"Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007, 146:857-67. 10.7326\/0003-4819-146-12-200706190-00007","journal-title":"Ann Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)92358-Z","article-title":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group","volume":"342","year":"1993","unstructured":"Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet. 1993, 342.1255-62. 10.1016\/0140-6736(93)92358-Z","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano RP","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E, et al.. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013, 369:2093-104. 10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/23969873241251931","article-title":"Timing of oral anticoagulants initiation for atrial fibrillation after acute ischemic stroke: a systematic review and meta-analysis","volume":"9","author":"Palaiodimou L","year":"2024","unstructured":"Palaiodimou L, Stefanou MI, Katsanos AH, et al.. Timing of oral anticoagulants initiation for atrial fibrillation after acute ischemic stroke: a systematic review and meta-analysis. Eur Stroke J. 2024, 9:885-95. 10.1177\/23969873241251931","journal-title":"Eur Stroke J"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07336-w","article-title":"Efficacy and safety of direct oral anticoagulants (DOACs) versus Warfarin in atrial fibrillation patients with prior stroke: a systematic review and meta-analysis","volume":"37","author":"Umashankar K","year":"2023","unstructured":"Umashankar K, Mammi M, Badawoud E, et al.. Efficacy and safety of direct oral anticoagulants (DOACs) versus Warfarin in atrial fibrillation patients with prior stroke: a systematic review and meta-analysis. Cardiovasc Drugs Ther. 2023, 37:1225-37. 10.1007\/s10557-022-07336-w","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.2099","article-title":"Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study","volume":"76","author":"Xian Y","year":"2019","unstructured":"Xian Y, Xu H, O'Brien EC, et al.. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) study. JAMA Neurol. 2019, 76:1192-202. 10.1001\/jamaneurol.2019.2099","journal-title":"JAMA Neurol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.007034","article-title":"Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study","volume":"6","author":"Paciaroni M","year":"2017","unstructured":"Paciaroni M, Agnelli G, Falocci N, et al.. Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin-K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc. 2017, 6:10.1161\/JAHA.117.007034","journal-title":"J Am Heart Assoc"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5058","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez JA","year":"2017","unstructured":"L\u00f3pez-L\u00f3pez JA, Sterne JA, Thom HH, et al.. Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis. BMJ. 2017, 359:j5058. 10.1136\/bmj.j5058","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.57656","article-title":"Comparison of effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with valvular atrial fibrillation: a network meta-analysis of randomized-control trials and observational studies","volume":"16","author":"Huma H","year":"2024","unstructured":"Huma H, Rawat A, Kaur M, et al.. Comparison of effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with valvular atrial fibrillation: a network meta-analysis of randomized-control trials and observational studies. Cureus. 2024, 16:e57656. 10.7759\/cureus.57656","journal-title":"Cureus"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1155\/cdr\/9923772","article-title":"Effectiveness and safety of dose-specific DOACs in patients with atrial fibrillation: a systematic review and network meta-analysis","volume":"2025","author":"Oh SH","year":"2025","unstructured":"Oh SH, Cheon S, Choi SY, Kim YS, Choi HG, Chung JE. Effectiveness and safety of dose-specific DOACs in patients with atrial fibrillation: a systematic review and network meta-analysis. Cardiovasc Ther. 2025, 2025:9923772. 10.1155\/cdr\/9923772","journal-title":"Cardiovasc Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy802","article-title":"Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials","volume":"40","author":"Wang KL","year":"2019","unstructured":"Wang KL, Lopes RD, Patel MR, B\u00fcller HR, Tan DS, Chiang CE, Giugliano RP. Efficacy and safety of reduced-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: a meta-analysis of randomized controlled trials. Eur Heart J. 2019, 40:1492-500. 10.1093\/eurheartj\/ehy802","journal-title":"Eur Heart J"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2021.10.027","article-title":"Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation","volume":"62","author":"Kido K","year":"2022","unstructured":"Kido K, Shimizu M, Shiga T, Hashiguchi M. Meta-analysis comparing inappropriately low dose versus standard dose of direct oral anticoagulants in patients with atrial fibrillation. J Am Pharm Assoc (2003). 2022, 62:487-95.e2. 10.1016\/j.japh.2021.10.027","journal-title":"J Am Pharm Assoc (2003)"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207422","article-title":"Association of alternative anticoagulation strategies and outcomes in patients with ischemic stroke while taking a direct oral anticoagulant","volume":"101","author":"Ip YM","year":"2023","unstructured":"Ip YM, Lau KK, Ko H, et al.. Association of alternative anticoagulation strategies and outcomes in patients with ischemic stroke while taking a direct oral anticoagulant. Neurology. 2023, 101:e358-69. 10.1212\/WNL.0000000000207422","journal-title":"Neurology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616659411","article-title":"Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis","volume":"9","author":"Katsanos AH","year":"2016","unstructured":"Katsanos AH, Mavridis D, Parissis J, et al.. Novel oral anticoagulants for the secondary prevention of cerebral ischemia: a network meta-analysis. Ther Adv Neurol Disord. 2016, 9:359-68. 10.1177\/1756285616659411","journal-title":"Ther Adv Neurol Disord"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.ibneur.2025.11.007","article-title":"Impact of direct oral anticoagulants on blood-brain barrier integrity","volume":"19","author":"Sato K","year":"2025","unstructured":"Sato K, Morofuji Y, Shinya D, Nakagawa S, Matsuo T. Impact of direct oral anticoagulants on blood-brain barrier integrity. IBRO Neurosci Rep. 2025, 19:931-5. 10.1016\/j.ibneur.2025.11.007","journal-title":"IBRO Neurosci Rep"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00676-2","article-title":"Timing of anticoagulation after ischaemic stroke and atrial fibrillation: better swift than sorry","volume":"406","author":"Ziai WC","year":"2025","unstructured":"Ziai WC, Tsivgoulis G. Timing of anticoagulation after ischaemic stroke and atrial fibrillation: better swift than sorry. Lancet. 2025, 406:3-5. 10.1016\/S0140-6736(25)00676-2","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.115.010049","article-title":"The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy","volume":"46","author":"von Kummer R","year":"2015","unstructured":"von Kummer R, Broderick JP, Campbell BC, et al.. The Heidelberg bleeding classification: classification of bleeding events after ischemic stroke and reperfusion therapy. Stroke. 2015, 46:2981-6. 10.1161\/STROKEAHA.115.010049","journal-title":"Stroke"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01377-1","article-title":"Hemorrhagic conversion of acute ischemic stroke","volume":"20","author":"Zubair AS","year":"2023","unstructured":"Zubair AS, Sheth KN. Hemorrhagic conversion of acute ischemic stroke. Neurotherapeutics. 2023, 20:705-11. 10.1007\/s13311-023-01377-1","journal-title":"Neurotherapeutics"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.125.051457","article-title":"Anticoagulation timing in acute stroke with atrial fibrillation according to chronic kidney disease: the OPTIMAS trial","volume":"56","author":"Nash PS","year":"2025","unstructured":"Nash PS, Dehbi HM, Ahmed N, et al.. Anticoagulation timing in acute stroke with atrial fibrillation according to chronic kidney disease: the OPTIMAS trial. Stroke. 2025, 56:1970-9. 10.1161\/STROKEAHA.125.051457","journal-title":"Stroke"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.036695","article-title":"Practical \u201c1-2-3-4-day\u201d rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: combined hospital-based cohort study","volume":"53","author":"Kimura S","year":"2022","unstructured":"Kimura S, Toyoda K, Yoshimura S, et al.. Practical \u201c1-2-3-4-day\u201d rule for starting direct oral anticoagulants after ischemic stroke with atrial fibrillation: combined hospital-based cohort study. Stroke. 2022, 53:1540-9. 10.1161\/STROKEAHA.121.036695","journal-title":"Stroke"},{"key":"ref40","unstructured":"Acute stroke management. (2022). Accessed. Feb 22, 2026: https:\/\/www.strokebestpractices.ca\/recommendations\/acute-stroke-management\/acute-antithrombotic-therapy.."},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1177\/23969873251357151","article-title":"Hemorrhagic transformation after endovascular treatment: baseline infarct volume is a better predictor than infarct growth rate","author":"M\u00e9ot M","year":"2025","unstructured":"M\u00e9ot M, Munsch F, Lapergue B, et al.. Hemorrhagic transformation after endovascular treatment: baseline infarct volume is a better predictor than infarct growth rate. Eur Stroke J. 2025, 23969873251357151. 10.1177\/23969873251357151","journal-title":"Eur Stroke J"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.109.573063","article-title":"Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial","volume":"41","author":"England TJ","year":"2010","unstructured":"England TJ, Bath PM, Sare GM, et al.. Asymptomatic hemorrhagic transformation of infarction and its relationship with functional outcome and stroke subtype: assessment from the Tinzaparin in Acute Ischaemic Stroke Trial. Stroke. 2010, 41:2834-9. 10.1161\/STROKEAHA.109.573063","journal-title":"Stroke"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.593098","article-title":"Is this contrast? Is this blood? An agreement study on post-thrombectomy computed tomography scans","volume":"11","author":"Lun R","year":"2020","unstructured":"Lun R, Walker GB, Guenego A, et al.. Is this contrast? Is this blood? An agreement study on post-thrombectomy computed tomography scans. Front Neurol. 2020, 11:593098. 10.3389\/fneur.2020.593098","journal-title":"Front Neurol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/ene.13859","article-title":"Hemorrhagic transformation after stroke: inter- and intrarater agreement","volume":"26","author":"Guenego A","year":"2019","unstructured":"Guenego A, Lecler A, Raymond J, et al.. Hemorrhagic transformation after stroke: inter- and intrarater agreement. Eur J Neurol. 2019, 26:476-82. 10.1111\/ene.13859","journal-title":"Eur J Neurol"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1161\/01.str.20.7.864","article-title":"Measurements of acute cerebral infarction: a clinical examination scale","volume":"20","author":"Brott T","year":"1989","unstructured":"Brott T, Adams HP Jr, Olinger CP, et al.. Measurements of acute cerebral infarction: a clinical examination scale. Stroke. 1989, 20:864-70. 10.1161\/01.str.20.7.864","journal-title":"Stroke"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.3174\/ajnr.A8307","article-title":"Risk of hemorrhagic transformation after mechanical thrombectomy without versus with IV thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of randomized clinical trials","volume":"45","author":"Jazayeri SB","year":"2024","unstructured":"Jazayeri SB, Ghozy S, Hemmeda L, Bilgin C, Elfil M, Kadirvel R, Kallmes DF. Risk of hemorrhagic transformation after mechanical thrombectomy without versus with IV thrombolysis for acute ischemic stroke: a systematic review and meta-analysis of randomized clinical trials. AJNR Am J Neuroradiol. 2024, 45:1246-52. 10.3174\/ajnr.A8307","journal-title":"AJNR Am J Neuroradiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.125.050646","article-title":"Prior reperfusion strategy does not modify outcome in early versus late start of anticoagulants in patients with ischemic stroke: prespecified subanalysis of the randomized controlled ELAN trial","volume":"56","author":"Wouters A","year":"2025","unstructured":"Wouters A, Demeestere J, Rossel JB, et al.. Prior reperfusion strategy does not modify outcome in early versus late start of anticoagulants in patients with ischemic stroke: prespecified subanalysis of the randomized controlled ELAN trial. Stroke. 2025, 56:2000-8. 10.1161\/STROKEAHA.125.050646","journal-title":"Stroke"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.118.024754","article-title":"Imaging findings after mechanical thrombectomy in acute ischemic stroke","volume":"50","author":"Puntonet J","year":"2019","unstructured":"Puntonet J, Richard ME, Edjlali M, et al.. Imaging findings after mechanical thrombectomy in acute ischemic stroke. Stroke. 2019, 50:1618-25. 10.1161\/STROKEAHA.118.024754","journal-title":"Stroke"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11174981","article-title":"Early anticoagulation in patients with acute ischemic stroke due to atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Palaiodimou L","year":"2022","unstructured":"Palaiodimou L, Stefanou MI, Katsanos AH, et al.. Early anticoagulation in patients with acute ischemic stroke due to atrial fibrillation: a systematic review and meta-analysis. J Clin Med. 2022, 11:10.3390\/jcm11174981","journal-title":"J Clin Med"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000133341.74387.96","article-title":"Contribution of susceptibility-weighted imaging to acute stroke assessment","volume":"35","author":"Hermier M","year":"2004","unstructured":"Hermier M, Nighoghossian N. Contribution of susceptibility-weighted imaging to acute stroke assessment. Stroke. 2004, 35:1989-94. 10.1161\/01.STR.0000133341.74387.96","journal-title":"Stroke"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000114201.11353.C5","article-title":"Magnetic resonance imaging improves detection of intracerebral hemorrhage over computed tomography after intra-arterial thrombolysis","volume":"35","author":"Greer DM","year":"2004","unstructured":"Greer DM, Koroshetz WJ, Cullen S, Gonzalez RG, Lev MH. Magnetic resonance imaging improves detection of intracerebral hemorrhage over computed tomography after intra-arterial thrombolysis. Stroke. 2004, 35:491-5. 10.1161\/01.STR.0000114201.11353.C5","journal-title":"Stroke"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1093\/europace\/euab065","article-title":"2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"23","author":"Steffel J","year":"2021","unstructured":"Steffel J, Collins R, Antz M, et al.. 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace. 2021, 23:1612-76. 10.1093\/europace\/euab065","journal-title":"Europace"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.jstrokecerebrovasdis.2022.106507","article-title":"Timing of direct oral anticoagulants for hemorrhagic transformation after endovascular treatment in acute ischemic stroke","volume":"31","author":"Nishimoto T","year":"2022","unstructured":"Nishimoto T, Oka F, Okazaki K, Ishihara H. Timing of direct oral anticoagulants for hemorrhagic transformation after endovascular treatment in acute ischemic stroke. J Stroke Cerebrovasc Dis. 2022, 31:106507. 10.1016\/j.jstrokecerebrovasdis.2022.106507","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.124.069324","article-title":"Early versus late initiation of direct oral anticoagulants after ischemic stroke in people with atrial fibrillation and hemorrhagic transformation: prespecified subanalysis of the randomized controlled ELAN trial","volume":"150","author":"Rohner R","year":"2024","unstructured":"Rohner R, Kneihsl M, Goeldlin MB, et al.. Early versus late initiation of direct oral anticoagulants after ischemic stroke in people with atrial fibrillation and hemorrhagic transformation: prespecified subanalysis of the randomized controlled ELAN trial. Circulation. 2024, 150:19-29. 10.1161\/CIRCULATIONAHA.124.069324","journal-title":"Circulation"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1227\/neu.0000000000002625","article-title":"Resuming anticoagulants in patients with intracranial hemorrhage: a meta-analysis and literature review","volume":"94","author":"El Naamani K","year":"2024","unstructured":"El Naamani K, Abbas R, Ghanem M, et al.. Resuming anticoagulants in patients with intracranial hemorrhage: a meta-analysis and literature review. Neurosurgery. 2024, 94:14-9. 10.1227\/neu.0000000000002625","journal-title":"Neurosurgery"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2023.10.020","article-title":"Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage","volume":"22","author":"Grainger BT","year":"2024","unstructured":"Grainger BT, McFadyen JD, Tran H. Between a rock and a hard place: resumption of oral anticoagulant therapy after intracranial hemorrhage. J Thromb Haemost. 2024, 22:594-603. 10.1016\/j.jtha.2023.10.020","journal-title":"J Thromb Haemost"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15482","article-title":"Prognostic significance of the clinical and radiological haemorrhagic transformation subtypes in acute ischaemic stroke: A systematic review and meta-analysis","volume":"29","author":"He J","year":"2022","unstructured":"He J, Fu F, Zhang W, Zhan Z, Cheng Z. Prognostic significance of the clinical and radiological haemorrhagic transformation subtypes in acute ischaemic stroke: A systematic review and meta-analysis. Eur J Neurol. 2022, 29:3449-59. 10.1111\/ene.15482","journal-title":"Eur J Neurol"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1268839","article-title":"Association of non-contrast CT markers with long-term functional outcome in deep intracerebral hemorrhage","volume":"14","author":"K\u00f6lbl K","year":"2023","unstructured":"K\u00f6lbl K, Hock SW, Xu M, et al.. Association of non-contrast CT markers with long-term functional outcome in deep intracerebral hemorrhage. Front Neurol. 2023, 14:1268839. 10.3389\/fneur.2023.1268839","journal-title":"Front Neurol"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1161\/STROKEAHA.121.037974","article-title":"Early deterioration, hematoma expansion, and outcomes in deep versus lobar intracerebral hemorrhage: the FAST trial","volume":"53","author":"Kuohn LR","year":"2022","unstructured":"Kuohn LR, Witsch J, Steiner T, et al.. Early deterioration, hematoma expansion, and outcomes in deep versus lobar intracerebral hemorrhage: the FAST trial. Stroke. 2022, 53:2441-8. 10.1161\/STROKEAHA.121.037974","journal-title":"Stroke"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/9233559","article-title":"Different effects of hematoma expansion on short-term functional outcome in basal ganglia and thalamic hemorrhages","volume":"2021","author":"Deng L","year":"2021","unstructured":"Deng L, Chen K, Yang L, Deng Z, Zheng H. Different effects of hematoma expansion on short-term functional outcome in basal ganglia and thalamic hemorrhages. Biomed Res Int. 2021, 2021:9233559. 10.1155\/2021\/9233559","journal-title":"Biomed Res Int"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-020-00720-5","article-title":"Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist's perspective","volume":"33","author":"Ravera M","year":"2020","unstructured":"Ravera M, Bussalino E, Fusaro M, Di Lullo L, Aucella F, Paoletti E. Systematic DOACs oral anticoagulation in patients with atrial fibrillation and chronic kidney disease: the nephrologist's perspective. J Nephrol. 2020, 33:483-95. 10.1007\/s40620-020-00720-5","journal-title":"J Nephrol"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1586\/17474086.2015.1111756","article-title":"Direct factor Xa inhibitor edoxaban: from bench to clinical practice","volume":"8","author":"Brekelmans M","year":"2015","unstructured":"Brekelmans M, Middeldorp S, Coppens M. Direct factor Xa inhibitor edoxaban: from bench to clinical practice. Expert Rev Hematol. 2015, 8:707-25. 10.1586\/17474086.2015.1111756","journal-title":"Expert Rev Hematol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/1753944717714921","article-title":"Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment","volume":"11","author":"Turpie AG","year":"2017","unstructured":"Turpie AG, Purdham D, Ciaccia A. Nonvitamin K antagonist oral anticoagulant use in patients with renal impairment. Ther Adv Cardiovasc Dis. 2017, 11:243-56. 10.1177\/1753944717714921","journal-title":"Ther Adv Cardiovasc Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/459940-timing-of-doac-initiation-after-atrial-fibrillation-related-acute-ischemic-stroke-a-unified-protocol-harmonizing-clinical-safety-and-imaging-based-precision-in-the-post-catalyst-era","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T17:37:27Z","timestamp":1774028247000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/459940-timing-of-doac-initiation-after-atrial-fibrillation-related-acute-ischemic-stroke-a-unified-protocol-harmonizing-clinical-safety-and-imaging-based-precision-in-the-post-catalyst-era"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":63,"URL":"https:\/\/doi.org\/10.7759\/cureus.105563","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,20]]}}}